CY1119353T1 - Θεραπευτικη χρηση αντισωματων anti-cs1 - Google Patents

Θεραπευτικη χρηση αντισωματων anti-cs1

Info

Publication number
CY1119353T1
CY1119353T1 CY20171100980T CY171100980T CY1119353T1 CY 1119353 T1 CY1119353 T1 CY 1119353T1 CY 20171100980 T CY20171100980 T CY 20171100980T CY 171100980 T CY171100980 T CY 171100980T CY 1119353 T1 CY1119353 T1 CY 1119353T1
Authority
CY
Cyprus
Prior art keywords
antagonists
bind
subject
present disclosure
antibody treatment
Prior art date
Application number
CY20171100980T
Other languages
English (en)
Inventor
Marna Williams
Yun J Tso
Nicolas F Landolfi
Gao Liu
David B Powers
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of CY1119353T1 publication Critical patent/CY1119353T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Luminescent Compositions (AREA)
  • Glass Compositions (AREA)

Abstract

Η παρούσα αποκάλυψη αφορά ανταγωνιστές του CS1 που δεσμεύονται με CS1 και εξουδετερώνουν τουλάχιστον μία βιολογική δραστικότητα του. Η αποκάλυψη περιλαμβάνει επίσης φαρμακευτική σύνθεση που περιλαμβάνει τέτοια αντισώματα ή θραύσματα αυτών που δεσμεύονται με το αντιγόνο. Η παρούσα αποκάλυψη παρέχει επίσης μέθοδο πρόληψης ή θεραπευτικής αγωγής καταστάσεων ασθενειών που περιλαμβάνουν αυτοάνοσες διαταραχές και καρκίνο, σε υποκείμενο που χρήζει αγωγής, η οποία μέθοδος περιλαμβάνει χορήγηση αποτελεσματικής ποσότητας τέτοιων ανταγωνιστών σε αυτό το υποκείμενο.
CY20171100980T 2003-05-08 2017-09-15 Θεραπευτικη χρηση αντισωματων anti-cs1 CY1119353T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US55762104P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
EP04760993A EP1624892B1 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-cs1 antibodies
EP10183377.0A EP2371391B1 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-CS1 antibodies

Publications (1)

Publication Number Publication Date
CY1119353T1 true CY1119353T1 (el) 2018-02-14

Family

ID=33459144

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20111100687T CY1111958T1 (el) 2003-05-08 2011-07-14 Θεραπευτικη χρηση αντισωματων anti-csi
CY20141100872T CY1115671T1 (el) 2003-05-08 2014-10-23 Θεραπευτικη χρηση αντισωματων anti-cs1
CY2016035C CY2016035I1 (el) 2003-05-08 2016-10-26 Θεραπευτικη χρηση αντισωματων anti-cs1
CY20171100980T CY1119353T1 (el) 2003-05-08 2017-09-15 Θεραπευτικη χρηση αντισωματων anti-cs1

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20111100687T CY1111958T1 (el) 2003-05-08 2011-07-14 Θεραπευτικη χρηση αντισωματων anti-csi
CY20141100872T CY1115671T1 (el) 2003-05-08 2014-10-23 Θεραπευτικη χρηση αντισωματων anti-cs1
CY2016035C CY2016035I1 (el) 2003-05-08 2016-10-26 Θεραπευτικη χρηση αντισωματων anti-cs1

Country Status (25)

Country Link
US (8) US20050025763A1 (el)
EP (4) EP2371391B1 (el)
JP (4) JP4887152B2 (el)
KR (1) KR101268707B1 (el)
CN (1) CN1805755B (el)
AT (1) ATE506076T1 (el)
AU (2) AU2004238363B2 (el)
BE (1) BE2016C056I2 (el)
BR (1) BRPI0410129B8 (el)
CA (1) CA2523001C (el)
CY (4) CY1111958T1 (el)
DE (1) DE602004032328D1 (el)
DK (3) DK1624892T3 (el)
ES (2) ES2643289T3 (el)
FR (1) FR16C1012I2 (el)
HK (3) HK1089374A1 (el)
HU (2) HUE034908T2 (el)
LT (1) LT2853272T (el)
LU (1) LU93274I2 (el)
MX (1) MXPA05012011A (el)
NL (1) NL300838I2 (el)
PL (3) PL2371391T3 (el)
PT (3) PT1624892E (el)
SI (3) SI1624892T1 (el)
WO (1) WO2004100898A2 (el)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
PL2641601T3 (pl) 2006-08-07 2017-01-31 Abbvie Biotherapeutics Inc. Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na zastosowaniu HuLuc63 i bortezomibu
EP2069478A2 (en) * 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
US7842293B2 (en) * 2006-08-07 2010-11-30 Facet Biotech Corporation Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
WO2009149021A2 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
BRPI0921433A2 (pt) * 2008-10-31 2017-06-06 Abbott Biotherapeutics Corp uso de anticorpos anti-cs1 para o tratamento de linfomas raros
JP5818688B2 (ja) * 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 核酸増幅反応の効率を改善するための方法および組成物
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
AU2011209713B2 (en) * 2010-01-28 2014-04-03 Glaxo Group Limited CD127 binding proteins
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
CA3182262A1 (en) 2011-04-01 2012-10-04 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
SG10201804260QA (en) 2012-08-31 2018-07-30 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
AU2014233528B2 (en) * 2013-03-15 2019-02-28 Abbvie Biotherapeutics Inc. Fc variants
CN105377892A (zh) * 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
AU2014259675B2 (en) * 2013-05-03 2019-05-02 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells
US20160159918A1 (en) * 2013-07-24 2016-06-09 The General Hospital Corporation Methods for diagnosing and treating immune disease
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US9482289B2 (en) 2013-10-14 2016-11-01 Club Car, Llc Self-preloading shift lever
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
PT3157561T (pt) * 2014-06-17 2020-03-25 Univ California Anticorpos contra alfa-v beta-8 melhorados
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
EP3212668B1 (en) * 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
DE102015102183B4 (de) * 2015-02-16 2018-03-01 Robert Bosch Automotive Steering Gmbh Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
WO2016168769A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
PT3313528T (pt) 2015-06-29 2021-09-16 Bristol Myers Squibb Co Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
AU2018235772A1 (en) * 2017-03-13 2019-09-26 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
CN110382546B (zh) 2017-03-29 2024-08-09 新加坡科技研究局 抗寡糖抗体
WO2018234370A1 (en) 2017-06-20 2018-12-27 Institut Curie DEFECTIVE IMMUNE CELLS AGAINST SUV39H1
CN111133002B (zh) * 2017-08-07 2024-05-24 恩比伊治疗股份公司 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN111542596A (zh) 2017-11-01 2020-08-14 朱诺治疗学股份有限公司 产生工程化细胞的治疗性组合物的方法
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
TW201932482A (zh) 2017-11-01 2019-08-16 美商奇諾治療有限公司 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
MX2020004239A (es) 2017-11-01 2020-09-09 Juno Therapeutics Inc Proceso para producir una composicion de celulas t.
JP2021505168A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 操作されたｔ細胞の組成物を製造するための方法
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
MA52235A (fr) * 2018-03-05 2021-02-17 Janssen Pharmaceutica Nv Anticorps anti-phf-tau et leurs utilisations
EP3814369A1 (en) 2018-06-29 2021-05-05 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
SG11202101130VA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Methods for assessing integrated nucleic acids
CN109406798A (zh) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 肌酐酶法检测试剂盒
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
SG11202103873VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods for activating inactive immune cells and cancer treatment
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
SG11202111360YA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
AU2020318781A1 (en) 2019-07-23 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SUV39H1
EP4055392A1 (en) 2019-11-05 2022-09-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
CA3169809A1 (en) * 2020-02-05 2021-08-12 Navaux, Inc. Anti-hepsin antibodies and uses thereof
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
KR20230074713A (ko) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Socs1에 결함이 있는 면역 세포
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
AU6094696A (en) 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO2002102994A2 (en) 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
CA2284550A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
US20030187196A1 (en) * 1998-12-30 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2361293A1 (en) 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3750000A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2380355A1 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
PL358215A1 (en) * 2000-03-24 2004-08-09 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
NZ545176A (en) * 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002313559A1 (en) 2001-08-23 2003-03-10 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
BRPI0921433A2 (pt) 2008-10-31 2017-06-06 Abbott Biotherapeutics Corp uso de anticorpos anti-cs1 para o tratamento de linfomas raros
KR102028770B1 (ko) 2011-09-15 2019-10-04 컨버전트 인포메이션 테크놀로지스 게엠베하 로봇 프로그램의 자동 생성을 위한 시스템 및 방법
ES2741897T3 (es) 2012-02-13 2020-02-12 Radius Eng Inc Cartucho reutilizable para moldeo por inyección

Also Published As

Publication number Publication date
US20090238827A1 (en) 2009-09-24
US20200031929A1 (en) 2020-01-30
JP2017019795A (ja) 2017-01-26
SI2371391T1 (sl) 2014-12-31
LT2853272T (lt) 2017-10-10
KR101268707B1 (ko) 2013-05-29
US20090238835A1 (en) 2009-09-24
BRPI0410129B8 (pt) 2021-05-25
AU2004238363A1 (en) 2004-11-25
ATE506076T1 (de) 2011-05-15
EP2371391A1 (en) 2011-10-05
FR16C1012I1 (el) 2016-09-12
NL300838I2 (el) 2017-01-03
EP3275463A1 (en) 2018-01-31
CA2523001C (en) 2013-12-31
HK1163497A1 (en) 2012-09-14
US9175081B2 (en) 2015-11-03
SI1624892T1 (sl) 2011-08-31
US8445646B2 (en) 2013-05-21
US8133981B2 (en) 2012-03-13
JP5976288B2 (ja) 2016-08-23
EP2371391B1 (en) 2014-07-23
CY2016035I2 (el) 2017-09-13
EP1624892A4 (en) 2007-08-08
CN1805755A (zh) 2006-07-19
ES2643289T3 (es) 2017-11-22
HK1089374A1 (en) 2006-12-01
US20140065063A1 (en) 2014-03-06
JP6042834B2 (ja) 2016-12-14
DK2371391T3 (da) 2014-11-03
JP2014139187A (ja) 2014-07-31
EP1624892B1 (en) 2011-04-20
CA2523001A1 (en) 2004-11-25
US8008450B2 (en) 2011-08-30
CY1115671T1 (el) 2017-01-25
PT2371391E (pt) 2014-10-30
WO2004100898A2 (en) 2004-11-25
KR20060018837A (ko) 2006-03-02
BE2016C056I2 (el) 2023-08-09
LU93274I2 (fr) 2016-12-27
DK1624892T3 (da) 2011-08-08
PT1624892E (pt) 2011-07-12
CY2016035I1 (el) 2017-09-13
AU2004238363B2 (en) 2010-05-27
HUE034908T2 (hu) 2018-03-28
DK2853272T3 (da) 2017-11-06
EP2853272B1 (en) 2017-08-02
PL1624892T3 (pl) 2011-09-30
AU2010214661B2 (en) 2012-05-17
PT2853272T (pt) 2017-08-30
JP2007503465A (ja) 2007-02-22
FR16C1012I2 (fr) 2019-01-11
MXPA05012011A (es) 2006-02-03
SI2853272T1 (sl) 2017-10-30
US10442859B2 (en) 2019-10-15
US20100168397A1 (en) 2010-07-01
US20120064083A1 (en) 2012-03-15
WO2004100898A3 (en) 2005-08-18
JP2012121878A (ja) 2012-06-28
ES2516840T3 (es) 2014-10-31
EP2853272A1 (en) 2015-04-01
HK1208815A1 (en) 2016-03-18
BRPI0410129A (pt) 2006-05-16
PL2371391T3 (pl) 2015-01-30
CY1111958T1 (el) 2015-11-04
EP1624892A2 (en) 2006-02-15
DE602004032328D1 (de) 2011-06-01
JP4887152B2 (ja) 2012-02-29
US20160002335A1 (en) 2016-01-07
HUS1600042I1 (hu) 2016-11-28
AU2010214661A1 (en) 2010-09-16
CN1805755B (zh) 2011-06-01
BRPI0410129B1 (pt) 2020-02-11
US20050025763A1 (en) 2005-02-03
PL2853272T3 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
TH1601004178A (th) ฮิวเมนแอนติบอดีต่อ pd-1